Antitromboticne lastnosti petidomemetikov (Slovene)

Code

L3-2034 (C) - included in ARIS records

Head

PhD Mojca Stegnar

Period

7/1/2000 - 12/31/2002

Range in 2002

0.24 FTE

Science

Medical sciences (5)
Other (1)

Reseacher status

Researcher (5)
Junior expert or technical associate (1)

Education

Doctor's degree (4)
Master's degree (1)
Other (1)

Sex

Woman (4)
Man (2)

Status

Employed at RO and RRD (3)
No data on employment in RO (1)
Retired (2)

No. of publications

1–9 (1)
100–999 (5)

Projects / Programmes source: ARIS

source: ARIS

Antitromboticne lastnosti petidomemetikov (Slovene)

Research activity

Code	Science	Field	Subfield
3.06.00	Medical sciences	Cardiovascular system

Code	Science	Field
P320	Natural sciences and mathematics	Nucleic acids, protein synthesis

Keywords

thrombosis, thrombin, coagulation factor, proteinase inhibitor, antagonist, peptidomimetic, platelet, platelet aggregation, glycoproteine receptor, antithrombotic drug

Evaluation (rules)

source: COBISS

Evaluation of bibliographic research performance indicators according to ARIS methodology

Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases

source: WoS

source: Scopus

source: COBISS

Researchers (6)

no.	Code	Name and surname	Research area	Role	Period	No. of publicationsNo. of publications
1.	15637	PhD Mojca Božič Mijovski	Cardiovascular system	Researcher	2000 - 2002	211
2.	05965	PhD Matija Kozak	Cardiovascular system	Researcher	2000 - 2002	333
3.	05034	PhD Mojca Stegnar	Cardiovascular system	Head	2000 - 2002	343
4.	17725	Marinka Tehovnik		Researcher	2000 - 2002	1
5.	20128	PhD Alenka Trampuš Bakija	Cardiovascular system	Researcher	2000 - 2002	128
6.	03392	MSc Viktor Videčnik	Cardiovascular system	Researcher	2000 - 2002	103

Organisations (1)

no.	Code	Research organisation	City	Registration number	No. of publicationsNo. of publications
1.	0312	University Medical Centre Ljubljana	Ljubljana	5057272000	77,480

Abstract

Anticoagulants which are used for treatment of thrombosis have limitations due to side effects and complicated laboratory monitoring. Use of antiplatelet drugs is limited since they inhibit only certain activation processes. The aim of the project is to test antithrombotic properties of peptidomimetics (potential selective and reversible inhibitors of thrombin and platelet membrane glycoprotein receptor GP IIa/IIIb antagonists) in vitro in pure enzyme/inhibitor/substrate systems, in biological systems with clotting and platelet aggregation assays, in vivo in animals and in animal models of thrombosis. It is expected that substances which inhibit thrombin and platelet aggregation in nM concentrations will be found. These inhibitors would be basic substances for the development of antithrombotic dugs.